Welcome to CrownBio’s Blog where we share our thoughts
on the latest trends and hot stories in Oncology and CVMD


As scientists are learning about the heterogeneity between patients that supposedly have the same tumor, they are growing increasingly interested in understanding whether a given compound can be broadly efficacious or only applicable to a subset of patients with the same disease. Patient-derived xenografts (PDXs) are the model of choice to address these questions as they conserve the original features of a patient’s tumor. CrownBio is now launching HuScreen™ a new platform that allows the use of PDXs in large-scale screenings to evaluate the efficacy of multiple treatments at the same time.

Read more

At the beginning of the last century lung cancer was a rare disease. However, as early as the end of the 1900s, it had already become the leading cause of preventable death worldwide. In 2016, the disease is expected to cause approximately 158,000 deaths in the United States alone, more than colorectal, breast, and prostate cancers combined. Therefore, finding a better cure for this deadly disease is a pressing need.

Read more